VEGFA and age-related macular degeneration: Anti-vascular endothelial growth factor (VEGF) therapy using ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA) or aflibercept (Eylea, Regeneron, Tarrytown, NY, and Bayer, Berlin, Germany) has become an evidence-based therapy for treating AMD worldwide after major clinical trials [4–6].